Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Haypp Group in connection with the listing on Nasdaq First North Growth Market
Mandate

Vinge advises Haypp Group in connection with the listing on Nasdaq First North Growth Market

October 13, 2021 Capital Markets and Public M&A M&A

Vinge advises Haypp Group AB (publ) (“Haypp Group”) in connection with the listing on Nasdaq First North Growth Market. The prospectus was published on 4 October 2021 and the first day of trading on Nasdaq First North Growth Market was 13 October 2021. The offering price was SEK 66 per share, corresponding to a market value of Haypp Group of approximately SEK 1,9 billion.

Haypp Group is an e-commerce business selling nicotine pouches and snus online in nine countries across Europe and in the US. The Company sells a broad selection of brands of any supplier in the category through a range of ten e-commerce platforms and brands, the largest of which is the Swedish snusbolaget.se. Haypp Group was founded in 2009 and is headquartered in Stockholm, Sweden.

The Vinge team mainly includes Christian Lindhé, Erik Sjöman, Kristian Ford (client responsible partner), Martin Svanberg and Johanne Örnfeldt Svensson (Capital Markets and Public M&A) as well as Niklas Törnell and Carl Trolle Olson (M&A).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025